Somatic mutations are a common molecular mechanism through which chronic myeloid leukemia (CML) cells acquire resistance to tyrosine kinase inhibitors (TKIs) therapy. While most of the mutations in the kinase domain of BCR-ABL1 can be successfully managed, the recurrent somatic mutations in other genes may be therapeutically challenging. Despite the major clinical relevance of mutation-associated resistance in CML, the mechanisms underlying mutation acquisition in TKI-treated leukemic cells are not well understood. This work demonstrated de novo acquisition of mutations on isolated single-cell sorted CML clones growing in the presence of imatinib. The acquisition of mutations was associated with the significantly increased expression of the LIG1 and PARP1 genes involved in the error-prone alternative nonhomologous end-joining pathway, leading to genomic instability, and increased expression of the UNG, FEN and POLD3 genes involved in the base-excision repair (long patch) pathway, allowing point mutagenesis. This work showed in vitro and in vivo that de novo acquisition of resistance-associated mutations in oncogenes is the prevalent method of somatic mutation development in CML under TKIs treatment.

1st Department of Internal Medicine Department of Hematology Charles University General Hospital Prague Prague Czechia

2nd Faculty of Medicine Charles University Prague Czechia

CLIP Childhood Leukaemia Investigation Prague Department of Paediatric Haematology and Oncology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czechia

Institute of Hematology and Blood Transfusion Prague Czechia

Institute of Pathological Physiology 1st Faculty of Medicine Charles University Prague Czechia

Zobrazit více v PubMed

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. . European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia. Leukemia (2020) 34(4):966–84. doi: 10.1038/s41375-020-0776-2 PubMed DOI PMC

Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. . Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2018) 16(9):1108–35. doi: 10.6004/jnccn.2018.0071 PubMed DOI

Quintás-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia. Cancer Control (2009) 16(2):122–31. doi: 10.1177/107327480901600204 PubMed DOI

Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O’Brien S, et al. . Frequency and Clinical Significance of BCR-ABL Mutations in Patients With Chronic Myeloid Leukemia Treated With Imatinib Mesylate. Leukemia (2006) 20(10):1767–73. doi: 10.1038/sj.leu.2404318 PubMed DOI

Kim T, Tyndel MS, Kim HJ, Ahn J, Choi SH, Park HJ, et al. . Spectrum of Somatic Mutation Dynamics in Chronic Myeloid Leukemia Following Tyrosine Kinase Inhibitor Therapy. Blood (2017) 129(1):38–47. doi: 10.1182/blood-2016-04-708560 PubMed DOI

Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, et al. . Laying the Foundation for Genomically-Based Risk Assessment in Chronic Myeloid Leukemia. Leukemia (2019) 33(8):1835–50. doi: 10.1038/s41375-019-0512-y PubMed DOI PMC

Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, et al. . High-Sensitivity Detection of BCR-ABL Kinase Domain Mutations in Imatinib-Naive Patients: Correlation With Clonal Cytogenetic Evolution But Not Response to Therapy. Blood (2005) 106(6):2128–37. doi: 10.1182/blood-2005-03-1036 PubMed DOI

Yuan H, Wang Z, Gao C, Chen W, Huang Q, Yee J, et al. . BCR-ABL Gene Expression is Required for its Mutations in a Novel KCL-22 Cell Culture Model for Acquired Resistance of Chronic Myelogenous Leukemia. J Biol Chem (2010) 285(7):5085–96. doi: 10.1074/jbc.M109.039206 PubMed DOI PMC

Wang Z, Yuan H, Roth M, Stark JM, Bhatia R, Chen WY. SIRT1 Deacetylase Promotes Acquisition of Genetic Mutations for Drug Resistance in CML Cells. Oncogene (2013) 32(5):589–98. doi: 10.1038/onc.2012.83 PubMed DOI PMC

Tobin LA, Robert C, Rapoport AP, Gojo I, Baer MR, Tomkinson AE, et al. . Targeting Abnormal DNA Double-Strand Break Repair in Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemias. Oncogene (2013) 32(14):1784–93. doi: 10.1038/onc.2012.203 PubMed DOI PMC

Muvarak N, Kelley S, Robert C, Baer MR, Perrotti D, Gambacorti-Passerini C, et al. . C-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias. Mol Cancer Res (2015) 13(4):699–712. doi: 10.1158/1541-7786.MCR-14-0422 PubMed DOI PMC

Pelák O, Kužílková D, Thürner D, Kiene M, Stanar K, Stuchlý J, et al. . Lymphocyte Enrichment Using CD81-Targeted Immunoaffinity Matrix. Cytometry A (2017) 91(1):62–72. doi: 10.1002/cyto.a.22918 PubMed DOI

Miller CA, McMichael J, Dang HX, Maher CA, Ding L, Ley TJ, et al. . Visualizing Tumor Evolution With the Fishplot Package for R. BMC Genomics (2016) 17(1):880. doi: 10.1186/s12864-016-3195-z PubMed DOI PMC

Wang Z, Liu Z, Wu X, Chu S, Wang J, Yuan H, et al. . ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance. PloS Genet (2014) 10(6):e1004414. doi: 10.1371/journal.pgen.1004414 PubMed DOI PMC

Carella AM, Garuti A, Cirmena G, Catania G, Rocco I, Palermo C, et al. . Kinase Domain Mutations of BCR-ABL Identified at Diagnosis Before Imatinib-Based Therapy are Associated With Progression in Patients With High Sokal Risk Chronic Phase Chronic Myeloid Leukemia. Leuk Lymphoma (2010) 51(2):275–8. doi: 10.3109/10428190903503446 PubMed DOI

Soverini S, de Benedittis C, Mancini M, Martinelli G. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk (2015) 15 Suppl:120. doi: 10.1016/j.clml.2015.02.035 PubMed DOI

Branford S, Wang P, Yeung DT, Thomson D, Purins A, Wadham C, et al. . Integrative Genomic Analysis Reveals Cancer-Associated Mutations at Diagnosis of CML in Patients With High-Risk Disease. Blood (2018) 132(9):948–61. doi: 10.1182/blood-2018-02-832253 PubMed DOI

Grossmann V, Kohlmann A, Klein H, Schindela S, Schnittger S, Dicker F, et al. . Targeted Next-Generation Sequencing Detects Point Mutations, Insertions, Deletions and Balanced Chromosomal Rearrangements as Well as Identifies Novel Leukemia-Specific Fusion Genes in a Single Procedure. Leukemia (2011) 25(4):671–80. doi: 10.1038/leu.2010.309 PubMed DOI

Khan M, Cortes J, Kadia T, Naqvi K, Brandt M, Pierce S, et al. . Clinical Outcomes and Co-Occurring Mutations in Patients With RUNX1-Mutated Acute Myeloid Leukemia. Int J Mol Sci (2017) 18(8):1618. doi: 10.3390/ijms18081618 PubMed DOI PMC

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. . Diagnosis and Management of AML in Adults: 2017 ELN Recommendations From an International Expert Panel. Blood (2017) 129(4):424–47. doi: 10.1182/blood-2016-08-733196 PubMed DOI PMC

Roche-Lestienne C, Deluche L, Corm S, Tigaud I, Joha S, Philippe N, et al. . RUNX1 DNA-Binding Mutations and RUNX1-PRDM16 Cryptic Fusions in BCR-ABL+ Leukemias are Frequently Associated With Secondary Trisomy 21 and may Contribute to Clonal Evolution and Imatinib Resistance. Blood (2008) 111(7):3735–41. doi: 10.1182/blood-2007-07-102533 PubMed DOI

Agarwal A, Eide CA, Harlow A, Corbin AS, Mauro MJ, Druker BJ, et al. . An Activating KRAS Mutation in Imatinib-Resistant Chronic Myeloid Leukemia. Leukemia (2008) 22(12):2269–72. doi: 10.1038/leu.2008.124 PubMed DOI

Martignoles J, Delhommeau F, Hirsch P. Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease. Int J Mol Sci (2018) 19(12):3850. doi: 10.3390/ijms19123850 PubMed DOI PMC

Adnan Awad S, Kankainen M, Ojala T, Koskenvesa P, Eldfors S, Ghimire B, et al. . Mutation Accumulation in Cancer Genes Relates to Nonoptimal Outcome in Chronic Myeloid Leukemia. Blood Adv (2020) 4(3):546–59. doi: 10.1182/bloodadvances.2019000943 PubMed DOI PMC

Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. . BCR-ABL1 Lymphoblastic Leukaemia is Characterized by the Deletion of Ikaros. Nature (2008) 453(7191):110–4. doi: 10.1038/nature06866 PubMed DOI

Grundschober E, Warsch W, Sexl V. The Transcription Factor STAT5 Drives Mutation and Imatinib Resistance in Chronic Myeloid Leukemia. Via ROS Prod BMC Pharmacol (2011) 11(Suppl 2):A22. doi: 10.1186/1471-2210-11-S2-A22 DOI

Nieborowska-Skorska M, Flis S, Skorski T. AKT-Induced Reactive Oxygen Species Generate Imatinib-Resistant Clones Emerging From Chronic Myeloid Leukemia Progenitor Cells. Leukemia (2014) 28(12):2416–8. doi: 10.1038/leu.2014.249 PubMed DOI PMC

Cheng Y, Hao Y, Zhang A, Hu C, Jiang X, Wu Q, et al. . Persistent STAT5-Mediated ROS Production and Involvement of Aberrant P53 Apoptotic Signaling in the Resistance of Chronic Myeloid Leukemia to Imatinib. Int J Mol Med (2018) 41(1):455–63. doi: 10.3892/ijmm.2017.3205 PubMed DOI

Pawlowska E, Blasiak J. DNA Repair–A Double-Edged Sword in the Genomic Stability of Cancer Cells–The Case of Chronic Myeloid Leukemia. Int J Mol Sci (2015) 16(11):27535–49. doi: 10.3390/ijms161126049 PubMed DOI PMC

Stoklosa T, Poplawski T, Koptyra M, Nieborowska-Skorska M, Basak G, Slupianek A, et al. . BCR/ABL Inhibits Mismatch Repair to Protect From Apoptosis and Induce Point Mutations. Cancer Res (2008) 68(8):2576–80. doi: 10.1158/0008-5472.CAN-07-6858 PubMed DOI

Singh P, Yang M, Dai H, Yu D, Huang Q, Tan W, et al. . Overexpression and Hypomethylation of Flap Endonuclease 1 Gene in Breast and Other Cancers. Mol Cancer Res (2008) 6(11):1710–7. doi: 10.1158/1541-7786.MCR-08-0269 PubMed DOI PMC

Becker JR, Gallo D, Leung W, Croissant T, Thu YM, Nguyen HD, et al. . Flap Endonuclease Overexpression Drives Genome Instability and DNA Damage Hypersensitivity in a PCNA-Dependent Manner. Nucleic Acids Res (2018) 46(11):5634–50. doi: 10.1093/nar/gky313 PubMed DOI PMC

Hirota K, Yoshikiyo K, Guilbaud G, Tsurimoto T, Murai J, Tsuda M, et al. . The POLD3 Subunit of DNA Polymerase δ can Promote Translesion Synthesis Independently of DNA Polymerase ζ. Nucleic Acids Res (2015) 43(3):1671–83. doi: 10.1093/nar/gkv023 PubMed DOI PMC

Parikh SS, Mol CD, Slupphaug G, Bharati S, Krokan HE, Tainer JA. Base Excision Repair Initiation Revealed by Crystal Structures and Binding Kinetics of Human Uracil-DNA Glycosylase With DNA. EMBO J (1998) 17(17):5214–26. doi: 10.1093/emboj/17.17.5214 PubMed DOI PMC

DeMott MS, Zigman S, Bambara RA. Replication Protein A Stimulates Long Patch DNA Base Excision Repair. J Biol Chem (1998) 273(42):27492–8. doi: 10.1074/jbc.273.42.27492 PubMed DOI

Limpose KL, Corbett AH, Doetsch PW. BERing the Burden of Damage: Pathway Crosstalk and Posttranslational Modification of Base Excision Repair Proteins Regulate DNA Damage Management. DNA Repair (Amst) (2017) 56:51–64. doi: 10.1016/j.dnarep.2017.06.007 PubMed DOI PMC

Iliakis G, Wang H, Perrault AR, Boecker W, Rosidi B, Windhofer F, et al. . Mechanisms of DNA Double Strand Break Repair and Chromosome Aberration Formation. Cytogenet Genome Res (2004) 104(1-4):14–20. doi: 10.1159/000077461 PubMed DOI

Xiong X, Du Z, Wang Y, Feng Z, Fan P, Yan C, et al. . 53BP1 Promotes Microhomology-Mediated End-Joining in G1-Phase Cells. Nucleic Acids Res (2015) 43(3):1659–70. doi: 10.1093/nar/gku1406 PubMed DOI PMC

Sallmyr A, Tomkinson AE, Rassool FV. Up-Regulation of WRN and DNA Ligase IIIalpha in Chronic Myeloid Leukemia: Consequences for the Repair of DNA Double-Strand Breaks. Blood (2008) 112(4):1413–23. doi: 10.1182/blood-2007-07-104257 PubMed DOI PMC

Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, et al. . BCR-ABL1 Mediated miR-150 Downregulation Through MYC Contributed to Myeloid Differentiation Block and Drug Resistance in Chronic Myeloid Leukemia. Haematologica (2018) 103(12):2016–25. doi: 10.3324/haematol.2018.193086 PubMed DOI PMC

O’Hare T, Eide CA, Deininger MWN. Bcr-Abl Kinase Domain Mutations, Drug Resistance, and the Road to a Cure for Chronic Myeloid Leukemia. Blood (2007) 110(7):2242–9. doi: 10.1182/blood-2007-03-066936 PubMed DOI

Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, et al. . Phosphorylation of the ATP-Binding Loop Directs Oncogenicity of Drug-Resistant BCR-ABL Mutants. Proc Natl Acad Sci U S A (2006) 103(51):19466–71. doi: 10.1073/pnas.0609239103 PubMed DOI PMC

Griswold IJ, MacPartlin M, Bumm T, Goss VL, O’Hare T, Lee KA, et al. . Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib. Mol Cell Biol (2006) 26(16):6082–93. doi: 10.1128/MCB.02202-05 PubMed DOI PMC

Miething C, Feihl S, Mugler C, Grundler R, von Bubnoff N, Lordick F, et al. . The Bcr-Abl Mutations T315I and Y253H do Not Confer a Growth Advantage in the Absence of Imatinib. Leukemia (2006) 20(4):650–7. doi: 10.1038/sj.leu.2404151 PubMed DOI

Hantel A, Larson RA. Imatinib is Still Recommended for Frontline Therapy for CML. Blood Adv (2018) 2(24):3648–52. doi: 10.1182/bloodadvances.2018018614 PubMed DOI PMC

Shih YT, Cortes JE, Kantarjian HM. Treatment Value of Second-Generation BCR-ABL1 Tyrosine Kinase Inhibitors Compared With Imatinib to Achieve Treatment-Free Remission in Patients With Chronic Myeloid Leukaemia: A Modelling Study. Lancet Haematol (2019) 6(8):e398–408. doi: 10.1016/S2352-3026(19)30087-0 PubMed DOI PMC

Schmitt MW, Pritchard JR, Leighow SM, Aminov BI, Beppu L, Kim DS, et al. . Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res (2018) 24(21):5321–34. doi: 10.1158/1078-0432.CCR-18-0167 PubMed DOI PMC

Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, et al. . Next-Generation Deep Sequencing Improves Detection of BCR-ABL1 Kinase Domain Mutations Emerging Under Tyrosine Kinase Inhibitor Treatment of Chronic Myeloid Leukemia Patients in Chronic Phase. J Cancer Res Clin Oncol (2015) 141(5):887–99. doi: 10.1007/s00432-014-1845-6 PubMed DOI

Dong Y, Gao X, Zhao Y, Wei M, Xu L, Yang G, et al. . Semi-random Mutagenesis Profile of BCR-ABL During Imatinib Resistance Acquirement in K562 Cells. Mol Med Rep (2017) 16(6):9409–14. doi: 10.3892/mmr.2017.7835 PubMed DOI PMC

Soverini S, Abruzzese E, Bocchia M, Bonifacio M, Galimberti S, Gozzini A, et al. . Next-Generation Sequencing for BCR-ABL1 Kinase Domain Mutation Testing in Patients With Chronic Myeloid Leukemia: A Position Paper. J Hematol Oncol (2019) 12(1):131. doi: 10.1186/s13045-019-0815-5 PubMed DOI PMC

Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events

Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations

New Inhibitors of Bcr-Abl Based on 2,6,9-Trisubstituted Purine Scaffold Elicit Cytotoxicity in Chronic Myeloid Leukemia-Derived Cell Lines Sensitive and Resistant to TKIs